Alimera Sciences (NASDAQ:ALIM) Stock Rating Lowered by HC Wainwright

Alimera Sciences (NASDAQ:ALIM) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Tuesday, Marketbeat.com reports. They currently have a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 8.70% from the stock’s previous close. HC Wainwright also issued estimates for Alimera Sciences’ Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.14 EPS.

ALIM has been the topic of several other reports. StockNews.com lowered Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Maxim Group initiated coverage on Alimera Sciences in a research note on Monday, March 25th. They set a “buy” rating and a $10.00 target price for the company.

Alimera Sciences Price Performance

Shares of ALIM opened at $5.52 on Tuesday. The stock has a market cap of $289.19 million, a P/E ratio of -3.52 and a beta of 1.14. Alimera Sciences has a 1 year low of $2.60 and a 1 year high of $5.65. The stock’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $3.66. The company has a current ratio of 2.62, a quick ratio of 2.51 and a debt-to-equity ratio of 1.71.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $23.01 million for the quarter, compared to the consensus estimate of $23.72 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. During the same period in the previous year, the business earned ($0.71) EPS. On average, equities analysts predict that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ALIM. Fifth Lane Capital LP bought a new stake in Alimera Sciences during the first quarter worth about $83,000. Hillsdale Investment Management Inc. acquired a new position in shares of Alimera Sciences during the 1st quarter worth approximately $169,000. Ancora Advisors LLC bought a new stake in shares of Alimera Sciences during the 1st quarter worth approximately $915,000. Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences in the 3rd quarter valued at approximately $1,840,000. Finally, Vanguard Group Inc. grew its stake in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares in the last quarter. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).